Free Trial

Rezolute (RZLT) Competitors

Rezolute logo
$8.69 -0.18 (-2.03%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$9.01 +0.32 (+3.68%)
As of 10/17/2025 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RZLT vs. CNTA, IMVT, TARS, CDTX, MOR, KNSA, MLYS, BEAM, NTLA, and HCM

Should you be buying Rezolute stock or one of its competitors? The main competitors of Rezolute include Centessa Pharmaceuticals (CNTA), Immunovant (IMVT), Tarsus Pharmaceuticals (TARS), Cidara Therapeutics (CDTX), MorphoSys (MOR), Kiniksa Pharmaceuticals International (KNSA), Mineralys Therapeutics (MLYS), Beam Therapeutics (BEAM), Intellia Therapeutics (NTLA), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.

Rezolute vs. Its Competitors

Centessa Pharmaceuticals (NASDAQ:CNTA) and Rezolute (NASDAQ:RZLT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

In the previous week, Centessa Pharmaceuticals had 6 more articles in the media than Rezolute. MarketBeat recorded 7 mentions for Centessa Pharmaceuticals and 1 mentions for Rezolute. Centessa Pharmaceuticals' average media sentiment score of 0.77 beat Rezolute's score of 0.00 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Centessa Pharmaceuticals
4 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Rezolute
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Centessa Pharmaceuticals' return on equity of -40.39% beat Rezolute's return on equity.

Company Net Margins Return on Equity Return on Assets
Centessa PharmaceuticalsN/A -40.39% -29.87%
Rezolute N/A -65.03%-58.86%

Centessa Pharmaceuticals currently has a consensus price target of $32.38, indicating a potential upside of 40.64%. Rezolute has a consensus price target of $14.50, indicating a potential upside of 66.86%. Given Rezolute's higher possible upside, analysts clearly believe Rezolute is more favorable than Centessa Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Centessa Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.91
Rezolute
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88

Centessa Pharmaceuticals has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500. Comparatively, Rezolute has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500.

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 7.1% of Centessa Pharmaceuticals shares are owned by company insiders. Comparatively, 14.8% of Rezolute shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Rezolute has lower revenue, but higher earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Centessa Pharmaceuticals$6.85M450.02-$235.76M-$1.79-12.86
RezoluteN/AN/A-$74.41M-$0.97-8.96

Summary

Centessa Pharmaceuticals beats Rezolute on 8 of the 14 factors compared between the two stocks.

Get Rezolute News Delivered to You Automatically

Sign up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RZLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RZLT vs. The Competition

MetricRezoluteMED IndustryMedical SectorNASDAQ Exchange
Market Cap$789.30M$3.45B$6.14B$10.56B
Dividend YieldN/A2.27%5.72%4.83%
P/E Ratio-8.9623.1685.7027.05
Price / SalesN/A487.09612.92132.35
Price / CashN/A45.2825.8230.35
Price / Book4.6710.3812.226.58
Net Income-$74.41M-$52.81M$3.33B$276.84M
7 Day Performance5.08%2.31%1.17%1.93%
1 Month Performance12.86%12.59%6.85%2.19%
1 Year Performance79.18%11.18%58.93%34.62%

Rezolute Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RZLT
Rezolute
2.1088 of 5 stars
$8.69
-2.0%
$14.50
+66.9%
+79.2%$789.30MN/A-8.9640
CNTA
Centessa Pharmaceuticals
3.5618 of 5 stars
$22.47
+0.7%
$32.38
+44.1%
+43.4%$2.99B$6.85M-12.55200News Coverage
Analyst Downgrade
Insider Trade
IMVT
Immunovant
2.2104 of 5 stars
$17.35
+1.9%
$30.38
+75.1%
-40.6%$2.97BN/A-6.09120Analyst Forecast
TARS
Tarsus Pharmaceuticals
1.2714 of 5 stars
$70.34
+0.3%
$66.67
-5.2%
+99.2%$2.96B$182.95M-30.1950
CDTX
Cidara Therapeutics
3.9045 of 5 stars
$116.15
+2.7%
$146.50
+26.1%
+801.6%$2.87B$1.27M-10.4490Analyst Forecast
Gap Down
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
KNSA
Kiniksa Pharmaceuticals International
3.3093 of 5 stars
$37.03
-2.3%
$45.43
+22.7%
+47.1%$2.81B$423.24M925.98220News Coverage
Analyst Forecast
Insider Trade
Analyst Revision
MLYS
Mineralys Therapeutics
1.9323 of 5 stars
$43.05
+2.1%
$43.50
+1.0%
+202.5%$2.80BN/A-12.0928News Coverage
Insider Trade
BEAM
Beam Therapeutics
3.5482 of 5 stars
$25.39
-3.5%
$45.92
+80.8%
+9.9%$2.66B$63.52M-5.64510
NTLA
Intellia Therapeutics
4.2718 of 5 stars
$23.76
-3.1%
$27.95
+17.6%
+17.4%$2.63B$57.88M-5.07600
HCM
HUTCHMED
2.5927 of 5 stars
$15.39
+2.1%
$20.88
+35.6%
-27.6%$2.63B$630.20M0.001,811

Related Companies and Tools


This page (NASDAQ:RZLT) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners